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With a series of reactions, biological molecules Dopamine and L-Dopa were conjugated with 
carborane in an effort to synthesize new boron delivery agents for a bimodal cancer treatment 
known as Boron Neutron Capture Therapy (BNCT). The products of these reactions were 
purified using column chromatography, and characterized with Fourier-Transform Infrared 
Spectroscopy (FT-IR) and Nuclear Magnetic Resonance (NMR) Spectroscopy. The successful 
synthesis of carborane-appended dopamine and L-Dopa has been supported with 
characterizations performed thus far. In the future, the compounds will undergo further analysis 
with elemental analysis, mass spectroscopy, and biodistribution studies to determine cytotoxicity 
and cellular uptake in the future.  
  
Introduction 
 Boron Neutron Capture Therapy (BNCT) is a bimodal cancer treatment which is based on 
the selective accumulation of Boron-10 (10B) atoms into cancer cells using biologically compatible 
boron delivery agents.1 10B can be irradiated with a beam of low-energy neutrons to produce 11B 
atoms. These atoms break down into Helium-4 (4He) alpha particles and Lithium-7 (7Li) atoms, 
and produce 2.4 MeV of energy.1 The high linear energy transfer (LET) alpha particles and 7Li 
particles travel approximately 5-9 µm, which is the dimeter of one cell.1,2 The distance traveled by 
these particles results in the destruction of only the cells containing a sufficient amount of 10B 
atoms (Figure 1).1,2 As cancer cells are selectively destroyed, the surrounding healthy cells are not 
affected.3 This greatly reduces the side effects associated with traditional cancer treatment methods 
such as chemotherapy and radiation. With the use of BNCT, patients will experience a better 
quality of life during their treatment.3 Therefore, selective accumulation of boron containing 
compounds into cancerous cells only is very desirable, and has become the focus of current 
research with BNCT.3  
 
Figure 1: BNCT Mechanism 
 Currently, there are only two boron delivery agents that have been approved by the FDA 
for clinical use. These compounds include boronophenylalanine fructose (BPA) and sodium 
borocaptate (BSH) (Figure 2).1 BPA is a derivative of amino acid tyrosine, and has been used to 
treat skin cancers, whereas BSH is a boron cluster which has been used to treat brain tumors.1 
Although successful, these compounds have limitations. BSH contains a sulfur atom, which can 
bond to other sulfur atoms to form disulfide bridges. This causes the formation of dangerous 
radicals in the body, and can cause negative side effects. BPA has only one Boron atom per 
molecule, and therefore requires high dosages for substantial boron accumulation into the cells. In 
order to successfully destroy a cancer cell, the boron content of that cell must be between 20-35 
µg/g of tumor tissue, but a low concentration of 10B must be maintained in surrounding healthy 
cells.1,2 Therefore, current research has been focused on the synthesis of new boron delivery agents 
that have a high concentration of boron atoms and are biologically compatible.  
 





Figure 2: (a) BSH (b) BPA 
Carborane is a biologically compatible molecule with a cage structure that contains ten 
boron atoms. Because of its properties, carborane would be an excellent boron carrier, and would 
allow faster accumulation of the necessary amount of boron in cancer cells. However, carborane 
cannot be taken up by cells on its own. Cancer cells take up large amounts of nutrients such as 
glucose, amino acids, and neurotransmitters to facilitate their rapid growth, but would not take up 
an individual carborane molecule. Therefore, by conjugating carborane with a molecule that would 
(a) (b) 
normally be taken up by cancer cells, the carborane cage can be disguised using the “Trojan Horse 
Method” and will be able to enter the cell. Although all cells will take up the carborane appended 
biomolecule, cancer cells will take up much larger amounts. Healthy cells will then metabolize the 
small amount of boronated compound, and it will safely exit the body. As cancerous cells will 
have a higher concentration of the boronated compound, some will still remain after it has been 
removed from the healthy cells. It is at that time that the neutron beam will irradiate the cancerous 
cells, and the reaction to destroy only those cells will occur. 
To successfully disguise the carborane cage and facilitate uptake by cancerous cells, 
carborane will be conjugated with Dopamine and L-Dopa. Dopamine is a neurotransmitter that 
plays a role in several functions such as movement, memory, the reward system, sleep, and mood, 
and is found in many locations throughout the body.4 L-Dopa is a precursor of Dopamine, and, 
unlike dopamine, can cross the blood-brain-barrier (BBB).4 To treat brain tumors, the boron carrier 
must be able to pass through the BBB, which is very selective. It is freely permeable to water, and 
is able to uptake molecules such as glucose, L-Dopa, and amino acids through selective 
transporters.5 Generally, the solubility of a compound in lipids positively correlates with the ability 
of a compound to pass through the blood brain barrier. Water and ethanol have high lipid solubility 
and can pass freely through the BBB, while L-Dopa and glucose have lower lipid solubility and 
require specific carriers to facilitate their passage (Figure 3).5 Although L-Dopa enters the brain 
quickly, enzymes called L-Dopa decarboxylase and monoamine oxidase break down L-Dopa and 
limit the amount that is able to enter the central nervous system.5 Because of this, large doses of 
the synthesized carborane-appended L-Dopa would be needed for effective BNCT treatment. 
However, a drug called carbidopa reduces decarboxylation of L-Dopa, and could be administered 
with L-Dopa to increase uptake.5 
 Figure 3: Uptake of various compounds through the BBB.5 
As the structures of both Dopamine and L-Dopa are very similar to that of BPA, the 
conjugation of Dopamine and L-Dopa with carborane could be viable options for the synthesis of 
boron delivery agents for BNCT.6 The synthesis of these new boron delivery agents would 
decrease side effects, as there would be no possibility of the formation of disulfide bridges, and 
would allow for high concentrations of boron to be taken up by the cells.6 Through the continuation 
of research, BNCT will improve and will become a safe and widely used method of treatment for 
many types of cancers. 
 
Materials and Methods 
Each reaction done in this research project has included the use of various laboratory 
equipment such as round bottom flasks, magnetic stir bar and hot plate, TLC paper, silica-gel 
column, ultraviolet lamp, rotary evaporator, and distilling apparatus including heating tape. The 
reactions were performed under argon or nitrogen gas using Schlenk lines to ensure an inert 
environment and ideal reaction conditions. The chemicals involved in these reactions were used 
without further purification and include previously prepared and purified 1-iodobutyl-o-carborane, 
dopamine HCl, L-Dopa, sodium hydroxide, hexane, hydrochloric acid, methanol, and 
dimethylformamide. The method by which 1-iodobutyl-o-caarborane was prepared can be seen in 
Scheme 1. 
 
Scheme 1: Synthesis of 1-iodopropyl-o-carborane 
1. Synthesis of Carborane Appended Dopamine 
 
Scheme 2: Synthesis of carborane-appended dopamine using dimethylformamide. 
Sodium hydroxide (160.3 mg, 4.00 mmol) was added to 100 mL DMF in an oven-dried 
250 mL round-bottom flask, and was sonicated for 30 minutes. After the sodium hydroxide had 
dissolved, dopamine hydrochloride (39.8 mg, 0.210 mmol) and 1-iodopropyl-o-carborane (129.7 
mg, 0.422 mmol) were added to the flask. The mixture was refluxed for 48 hours at 80oC. 
Following the reflux, the dimethylformamide solvent was removed in small fractions using 
distillation, leaving the crude product. This crude product was then purified using silica gel column 
chromatography (SiO2, eluted with hexane and dimethylformamide) and TLC (SiO2, developed 
with hexane, dimethylformamide). The solvent was then again removed from the purified product 
using distillation, and the product was dried under vacuum for 10 hours. The product was then 
characterized using Fourier-Transform Infrared Spectroscopy shown in Figure 4, and 1H, 11B, and 
13C NMR in dimethyl sulfoxide (DMSO) solvent shown in Figures 2, 3, and 4. In an effort to 
remove some of the excess salt that was formed during the reaction, a small portion of the product 
was washed with water. The washed product as well as the unwashed product were taken for 
characterization using elemental analysis, and the results were compared with the elemental 
analysis of unreacted dopamine hydrochloride (Table 1). 
 
2. Synthesis of Carborane Appended L-Dopa 
a. Protection of Carboxylic Acid using Fischer Esterification 
 

















First, 15 mL of methanol was added to a 50 mL round bottom flask. 49.8 mg of L-Dopa 
was measured using a laboratory balance and then was added to the flask. This was cooled with 
ice for five minutes before 1 mL concentrated HCl was added dropwise into the solution with 
continued cooling and stirring. The mixture was then allowed to return to room temperature before 
beginning reflux at 50oC. The reflux was continued overnight, and then the solvent was removed 
with rotary evaporation. The sticky yellow product was analyzed with Fourier Transform Infrared 
Spectroscopy, 1H NMR, and 13C NMR as seen in Figures 5, 6, and 7, respectively. Following this 
initial analysis, the product was dried further under vacuum conditions to produce an off-white, 
fluffy solid. This product was again analyzed using 1H NMR, 13C NMR, and FTIR as seen in 
Figures 8, 9, and 10, respectively. 
 
Reaction II: 
In order to produce a more substantial amount of product for use in the reaction depicted 
in Scheme 3, a larger scale reaction was completed. 60 mL methanol was added to a 250 mL round 
bottom flask. Then, 200.7 mg L-Dopa was added to the flask with a magnetic stir bar. This mixture 
was placed on ice to cool and stir for approximately five minutes before the addition of 4.2 mL 
concentrated HCl in a dropwise manner. The clear solution was allowed to stir on ice for 
approximately five minutes before being allowed to return to room temperature while stirring. The 
solution was then heated to 50oC to reflux overnight. The following day, the solvent was removed 
with rotary evaporation to produce a sticky yellow product as observed in Reaction I. This product 
was then dried under vacuum conditions overnight to produce an off-white, fluffy solid. 
 
b. Addition of Carborane Cage 
 
Scheme 4: Synthesis of carborane-appended L-Dopa 
 To finish the synthesis of carborane appended L-Dopa, the second part of the procedure 
was performed as follows. Sodium hydroxide (42.4 mg, 1.00 mmol) was added to 50 mL DMF 
in an oven-dried 250 mL round-bottom flask and was sonicated for 30 minutes. 50 mL DMF was 
also added to the flask containing the protected L-Dopa (281.4 mg, 1.33 mmol). Following the 
dissolution of the sodium hydroxide, the solution containing the protected L-Dopa and was 
added to the sodium hydroxide and DMF solution. Then, 1-iodopropyl-o-carborane (312.7 mg, 
1.01 mmol) was added to the flask. The solution was refluxed for 16 hours at 80oC before the 
solvent was removed through distillation. The product obtained from this reaction was then 





1. Synthesis of Carborane Appended Dopamine 
 
Figure 4: FTIR spectra of unreacted dopamine HCl (red) compared with purified carborane 
appended dopamine (blue). 
 
Figure 5: 1H NMR of purified carborane-appended dopamine. 
 
Figure 6: 13C NMR of purified carborane-appended dopamine. 
 
 
Figure 7: 11B NMR of purified carborane-appended dopamine 
Sample Expected Observed 
Dopamine Hydrochloride C: 50.67% C: 50.77% 
H: 6.38% H: 6.36% 
N: 7.39% N: 8.64% 
Carborane-Appended Dopamine 
(Before wash with DI water) 
C: 43.10% C: 39.88% 
H: 4.62% H: 8.75% 
N: 2.79% N: 12.05% 
Carborane-Appended Dopamine 
(After wash with DI water) 
C: 43.10% C: 49.37% 
H: 4.62% H: 9.85% 
N: 2.79% N: 3.09% 
 
Table 1: Elemental Analysis results for procedure outlined in Scheme 2. 
 
 
2. Synthesis of Carborane Appended L-Dopa 
 





Figure 8: Fourier Transform Infrared Spectroscopy of L-Dopa (Red) and L-Dopa with a methyl 
group protecting the carboxylic acid ((Blue) (Reaction I)) before drying. 
 
 
Figure 9: 1H NMR of protected L-Dopa before drying (Reaction I). 
 
Figure 10: 13C NMR of protected L-Dopa before drying (Reaction I) 
 
Figure 11: 1H NMR of protected L-Dopa following dying under vacuum conditions (Reaction 1). 
 
 





Figure 13: FTIR of protected L-Dopa following drying under vacuum conditions (Reaction I). 
 




Figure 14: FTIR of L-Dopa (red), methyl protected L-Dopa (dark blue), and carborane-
appended L-Dopa (bright blue). 
 
 




Figure 16: 13C NMR of carborane-appended L-Dopa 
  
 




1. Synthesis of Carborane Appended Dopamine 
When the product obtained as described in Scheme 2 was purified and the solvent was 
removed with distillation, it was dark brown in color and very waxy. Initially, it was 
hypothesized that there could be a small amount of DMF left in the product. After many hours of 
drying under vacuum, a brown clumpy solid was formed. In Figure 4, the FTIR spectra of 
dopamine hydrochloride and the purified carborane appended dopamine product are compared. 
The large peak at 3400 to 3000 cm-1 which represent the OH groups on the dopamine 
hydrochloride shifted to the left and centered at 3500 cm-1. This indicates that the OH groups 
were removed, and the peak at 3500 cm-1 is representative of the NH2 group in the carborane 
appended dopamine. Additionally, a strong peak appeared at 2500 cm-1 in the spectrum of the 
product, which is indicative of a B-H bond. This suggests that the carborane cage was 
successfully attached to the dopamine.  
The 11B NMR shown in Figure 7 further supports this conclusion, as there are ten peaks in 
the spectrum, which correspond to the ten boron atoms in a carborane cage. The 1H  NMR and 
13C NMR seen in Figures 5 and 6, respectively, are not as promising, as there are not as many 
signals as expected. Additionally, the results from elemental analysis can be seen in Table 1. The 
values obtained from the analysis of the carborane-appended dopamine product are slightly 
different from the expected values, but do not give reason to believe that the synthesis of the 
compound was unsuccessful. One of the most significant differences was in the nitrogen content 
of the carborane-appended dopamine before being washed with water. Rather than the expected 
2.79%, the nitrogen content was 12.05%. Additionally, before being washed with water, the 
carborane-appended dopamine exhibited a carbon content of 39.88%. After being washed with 
water, the carbon content increased to 49.37% as compared to the 43.10% that is expected. These 
discrepancies, although larger than would be normally accepted, can be attributed to the 
calibration curve that was produced by the elemental analysis apparatus. The calibration curve 
was significantly deviant from the normal range, and contributed to the value differences 
between expected and observed. Because of this, the results from elemental analysis are 
inconclusive. This method of characterization will therefore be performed again to obtain more 
credible results. 
2. Synthesis of Carborane Appended L-Dopa 
a. Protection of Carboxylic acid with Fischer Esterification 
After completion of the reaction outlined in Scheme 3 aimed to protect the carboxylic acid 
group with a methyl group, a sticky, yellow product was obtained. The product was characterized 
using FTIR and compared with the FTIR of the starting material L-Dopa, as seen in Figure 8. 
There are some differences in the spectra indicating that a favorable reaction did occur. Because 
the desired product has only one additional carbon that has replaced a hydroxyl group on the 
carboxylic acid, it is difficult to determine the success of the reaction solely from the FTIR Spectra. 
However, the desired peaks are present. In the spectrum of the product following drying under 
vacuum condition (Figure 13), a stretch at 1735 cm-1 indicates a carbonyl carbon, while stretches 
at 1287 cm-1and 1117 cm-1 indicate a C-O bond. Additionally, the large stretch at 3214 cm-1 
indicates the OH groups and NH3 groups that are still present on the L-Dopa.  
 In the 13C NMR spectra in Figure 12, the peaks at 110-120 ppm indicate a C-O bond. Likewise, 
the peak at approximately 3.8 ppm indicates the presence of an RO-CH3 bond in the
 1H NMR 
spectra (Figure 11). Additionally, in the 1H NMR (Figure 11), the peak at 10-13 ppm that would 
represent a carboxylic acid is not present. All of these peaks indicate that the reaction was 
successful in protecting the carboxylic acid with a methyl group. 
b. Addition of Carborane Cage 
From the characterizations obtained on the product from the reaction outlined in Scheme 3, it is 
promising that the desired compound, carborane-appended L-Dopa, was synthesized. In Figure 14, 
there is a characteristic peak at approximately 2600 cm-1 indicating the presence of B-H bonds. 
Additionally, the peak at approximately 3500 cm-1 is sharp, which means that there is an amine in 
the compound. The absence of the broad –OH peak at this location indicates that the carborane 
cages were attached to the –OH groups on the L-Dopa. The 11B NMR spectrum in Figure 17 shows 
10 peaks for the 10 boron atoms in a carborane cage. Additionally, the 13C NMR in Figure 16 has 
a peak at approximately 220 ppm indicating a carbonyl bond. The small peaks at approximately 
125 ppm indicate aromatic carbons, which are found in the ring. These peaks are all positive 
indications of the successful synthesis of carborane-appended L-Dopa.  
 
Conclusion 
 As the synthesis of these molecules has been determined to be successful thus far, it will 
be necessary to continue research on this subject in order to fully characterize the compounds and 
determine their biological compatibility. Mass spectrometry and additional trials in elemental 
analysis will further solidfy the identities of the compounds, and biodistribution studies will be 
conducted to determine each compound’s cytotoxicity and cellular uptake in cancer cell lines. With 
positive results in these areas, clinical trials would follow. With the successful synthesis of these 
boron delivery agents, Boron Neutron Capture Therapy will continue to make advancements, and 
the use of BNCT as a cancer treatment will become more widespread. Patients will benefit from 
advancements in this area by experiencing fewer side effects than with traditional cancer therapies, 
and fewer treatments overall.7 In addition to this avenue of research, future directions could include 
increasing tumor cell specificity and tissue selectivity for even more reduced side effects on 
healthy cells, exploring the development of neutron beams specifically for BNCT to improve 
treatment success, and investigating treatment planning including specific drug doses and timing 
of treatment for patients on an individual basis.8,9 Although there is much research to be done in 
this field, BNCT is a promising method of cancer therapy that will greatly benefit patients suffering 





1. Koganei, H.; Ueno, M.; Tachikawa, S.; Tasaki, L.; Seung Ban, H.; Suzuki, M.; Shiraishi, 
K.; Kawano, K.; Yokoyama, M.; Maitani, Y.; Ono, K.; Nakamura, H. Development of 
High Boron Content Liposomes and Their Promising Antitumor Effect for Neutron 
Capture Therapy of Cancers. Bioconjugate Chem. 2013, 24, 124-132. 
2. Cai, J.; Soloway, A.; Barth, R.; Adams, D.; Hariharan, J.; Wyzlic, I.; Radcliffe, K. Boron-
Containing Polyamines as DNA Targeting Agents for Neutron Capture Therapy of Brain 
Tumors: Synthesis and Biological Evaluation. J. Med. Chem. 1997, 40, 3997-3896. 
3. Soloway, A. H.; Tjarks, W.; Bamum, B. A.; Rong, F.; Barth, R. F.; Codogni, I. M.; 
Wilson, J. G. The Chemistry of Neutron Capture Therapy. Chem. Rev. 1998, 98, 1515-
1562. 
4. Lemke, T. L.; Williams, D. A. Foye’s Principles of Medicinal Chemistry. Jan 24, 2014, 
Lippincott Williams & Wilkins. 
5. Laterra J, Keep R, Betz L. A., et al. Blood—Brain Barrier. In: Siegel GJ, Agranoff BW, 
Albers RW, et al., editors. Basic Neurochemistry: Molecular, Cellular and Medical 
Aspects. Philadelphia: Lippincott-Raven; 1999, 6. 
6. Hattori, Y.; Kusaka, S.; Mukumoto, M.; Uehara, K.; Asano, T.; Suzuki, M.; Masunaga, 
S.; Ono, K.; Tanimori, S.; Kirihata, M. Biological Evaluation of Dodecaborate-
Containing L-Amino Acids for Boron Neutron Capture Therapy. J. Med. Chem. 2012, 55, 
6980-6984. 
7. Hosmane, N.; Maguire, J.; Zhu, Y.; Takagaki, M. Boron and Gadolinium Neutron 
Capture Therapy For Cancer Treatment. Singapore: World Scientific Pub, 2012.  
8. Tjarks, W.; Anisuzzaman, A. K. M.; Liu, L.; Soloway, A.; Barth, R.; Perkins, D. J.; 
Adams, D. M. Synthesis and In Vitro Evaluation of Boronated Uridine and Glucose 
Derivatives for Boron Neutron Capture Therapy. J. Med. Chem. 1992, 35, 1628-1633. 
9. Yinghuai, Z.; Hosmane, N.S. Applications and perspectives of boron-enriched 
nanocomposites in cancer therapy. Future Medicinal Chemistry, 2013, 5(6), pp 705-714.  
